Beta-blockers may improve survival in epithelial ovarian cancer
the ONA take:
Beta-blockers, particularly first-generation nonselective beta-blockers, improved overall survival among patients with epithelial ovarian cancer, according to a new study published today in the journal Cancer.
For the study, researchers from The University of Texas MD Anderson Cancer Center in Houston, TX, retrospectively analyzed the medical records of 1,425 women with epithelial ovarian cancer treated between 2000 and 2010 in order to evaluate the impact of beta-blocker use during chemotherapy on overall survival.
Among 269 patients who received beta-blocker therapy, about 72% received beta-1 adrenergic receptor selective agents like atenolol, metoprolol, and bisoprolol, while the rest received nonselective beta-blockers, such as propranolol, carvedilol, and labetalol.
Results showed that median overall survival for beta-blocker and non-beta-blocker users was 47.8 months and 42 months, respectively.
Researchers found that patients receiving selective beta-1 blockers had a median overall survival of 94.9 months vs 38 months for those receiving non-selective beta antagonists.
The researchers note, however, that further studies are required before beta-blockers are recommended as adjuvant therapy in patients with ovarian cancer undergoing surgery.
Beta-blockers, particularly first-generation nonselective beta-blockers, improved overall survival among patients with epithelial ovarian cancer.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|